places strain on blood bank inventories. Unlike many other blood products, platelets must be stored at room temperature, resulting in limited shelf-life and logistical difficulties regarding the optimal and most cost-effective approach to platelet handling. While the American Association of Blood Banks recommends prophylactic platelet transfusion in patients with decreased platelet production and platelet counts ≤10 × 10 9 /L, 6 thrombocytopenia in the critically ill is not always secondary to decreased production, and prophylactic transfusions are often provided at higher platelet count thresholds. 7 The objective of this study was to assess the impact of prophylactic platelet transfusion on bleeding complications in critically ill patients with thrombocytopenia. We hypothesized that platelet transfusions would not be associated with improved clinical outcomes.
Methods
This is a retrospective cohort study conducted under the approval of the Mayo Clinic (Rochester, MN) Institutional Review Board with a waived requirement for written informed consent. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines were used in the design and conduct of the study. 8 The study population included adult patients admitted to a medical, surgical, or combined medical-surgical ICU at an academic medical center. Basic ICU characteristics are provided in Supplemental Digital Content 1, Table 1 , http://links.lww.com/AA/C202. Inclusion criteria were age ≥18 years, ICU admission between January 1, 2009, and December 31, 2013, and the presence of a platelet count measured during ICU admission. For patients with multiple ICU admissions during the study period, only the first admission with a platelet count measurement was included. For patients with multiple platelet counts who did not receive platelet transfusion, the lowest platelet value was utilized as the qualifying platelet count. In patients with multiple platelet counts who did receive platelets during their first ICU admission, the platelet count immediately preceding platelet transfusion was utilized. Patients were excluded for lack of research authorization and prior inclusion in the study such that no patient was included twice. Patients receiving red blood cell (RBC) transfusion in the 24 hours before measurement of the qualifying platelet count were also excluded to minimize the risk of including those with active bleeding. Similarly, patients receiving RBC transfusion in the interval between platelet count measurement and platelet transfusion were also excluded.
The primary exposure variable was the presence or absence of prophylactic platelet transfusion in the 24 hours after measurement of the qualifying platelet count value. Prophylactic platelet transfusion was defined as the first platelet transfusion episode during the qualifying ICU admission, excluding those patients who had received RBC transfusion in the 24 hours before platelet count measurement or in the interval between platelet count measurement and platelet component administration. The presence and timing of all transfusion episodes were extracted from the electronic health record, with the timing of transfusion defined as the actual transfusion initiation time rather than the time of component issue from the blood bank. Of note, platelet transfusion orders at the study institution require selection of an indication from the following categories: platelet count ≤100 × 10 9 /L with active bleeding; ≤10 × 10 9 /L without active bleeding; ≤20 × 10 9 /L with fever, disseminated intravascular coagulation, sepsis, or other conditions associated with platelet destruction; ≤20 × 10 9 /L before central venous catheter insertion; ≤50 × 10 9 /L requiring surgery; and active bleeding in the presence of antiplatelet therapies at any platelet count. Ordering providers may also select "other" with subsequent free text entry of the indication, and hence platelet transfusions are not strictly per protocol. Additionally, no indication is required for transfusion orders placed in surgical/procedural suites or during massive transfusion protocols.
The primary outcome for this investigation was RBC transfusion within 24 hours of the qualifying platelet count value for nonplatelet-transfused patients and within 24 hours of platelet transfusion for platelet-transfused patients. Secondary outcome measures included ICU and hospital-free days (defined as 28 minus the ICU or hospital length of stay in days, with patients dying before discharge and those with ICU or hospital durations greater than 28 days receiving a score of zero), ICU mortality, all-cause mortality within 30 days of ICU discharge, and changes in sequential organ failure assessment (SOFA) score 24 hours after the qualifying platelet count or platelet transfusion for nontransfused and transfused patients, respectively.
Relevant information for study participants was extracted using the Acute Care DataMart, an institutional resource that contains clinical, demographic, transfusion, and laboratory data for patients admitted to the ICU. 9 Additional baseline characteristics were obtained from the Mayo Clinic Life Sciences System, a second institutional database. 10 Extensive validation has been performed on these databases, and the accuracy of extracted data is superior to that collected by manual methods.
11

Statistical Analysis
The binary end points of qualifying RBC transfusion (primary outcome), ICU mortality, and 30-day mortality were modeled using logistic regression. ICU and hospital-free day end points were modeled using negative binomial generalized linear models, while changes in SOFA scores from the time of platelet count measurement (controls) or platelet transfusion (cases) to 24 hours later were modeled using linear regression. To account for imbalances in measured covariates, individuals were matched with and without platelet transfusions using 1:1 propensity score matching without replacement. Missing data were imputed using recursive conditional mean imputation. The variable with the least missing was imputed first, then the variable with the next least missing, and so forth. Missing variables included hemoglobin (0.3%), international normalized ratio (21.0%), and activated partial thromboplastin time (aPTT) (35.0%). When comparing fully nonmissing patients to patients with any missing value, patients with any missing were less likely to receive prophylactic platelet transfusion (1.1%-4.7%), aspirin (45.0%-56.8%), warfarin (10.5%-26.8%), or be of male gender (53.7%-62.5%; data not shown). The assumption of missing at random appeared reasonable for all other variables. The propensity score was constructed from a logistic regression model and matching using the SAS macro %gmatch (greedy-matching algorithm). 12 The caliper width was set to 0.25 standard www.anesthesia-analgesia.org
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Prophylactic Platelets in the Critically Ill deviations of the logit propensity score. 13 To assess prematch and postmatch imbalances, standardized differences were estimated for all baseline covariates. 14 A standardized difference <10% was considered to be an adequate balance. It was decided a priori that any variables with inadequate balances would be adjusted for in the subsequent analyses. After matching, statistical analyses were performed as previously described for unmatched analyses. The primary analysis was the primary (RBC transfusion) and secondary outcomes (ICU mortality, all-cause 30-day mortality, ICUfree days, hospital-free days, and change in SOFA score) in the propensity score matched dataset.
To further assess the robustness of study findings, multiple a priori sensitivity analyses were planned including restriction to (1) patients with platelet counts ≤50 × 10 9 /L, which is commonly used as platelet transfusion threshold in surgical ICU patients and before invasive procedures; (2) patients with platelet counts ≤20 × 10 9 /L, which is a commonly utilized platelet transfusion threshold; (3) medical ICU patients; (4) surgical ICU patients; and (5) exclusion of patients requiring surgical or interventional procedures outside of the ICU environment (eg, interventional radiology procedures, complex endoscopy, coronary angiography) in the 24-hour period after platelet count measurement or platelet transfusion. This last sensitivity analysis was intended to mitigate the impact of the surgical procedure on subsequent RBC transfusions. Additionally, as a supplement to propensity-matched analyses, a multivariable regression model was run in the full cohort adjusting for all variables used in the propensity score matching.
It was decided a priori that an odds ratio of 1.5 for RBC transfusion in those who receive prophylactic transfusion compared to those who did not was clinically important. Assuming an RBC rate of 10% in those without prophylactic transfusion, we would have 80% power at .05 α significance level with 957 1:1 platelet transfusions to no platelet transfusion matched sets (α = .05, β = .20). The prophylactic transfusion rate was estimated to be 4%, thus we would need to examine ~24,000 study participants to acquire 957 patients with prophylactic platelet transfusion. This number was inflated to 31,000 to facilitate a priori sensitivity analyses. All analyses were performed using SAS version 9.4.
Results
A total of 45,785 patients were admitted to an eligible ICU during the study period with 40,693 (88.9%) meeting inclusion criteria ( Figure 1 ). Of the 37,466 patients not receiving platelets, 7017 were excluded for having received an RBC transfusion in the 24 hours preceding platelet count measurement. Of the 3227 patients receiving platelets, 2162 patients were excluded due to receiving RBCs in the 24 hours preceding platelet count measurement or platelet transfusion, creating a total cohort of 31,514 patients including 14,171 surgical patients, 10,162 medical patients, and 7181 patients in a mixed medicalsurgical ICU. In total, 1065 (3.4%) received a prophylactic platelet transfusion with a median (interquartile range) volume of 1 (1-1) unit. The median time between platelet count measurement and platelet transfusion was 2.8 (1.4-6.2) hours.
Comparison of baseline clinical, demographic, and laboratory characteristics between platelet-and nonplatelettransfused patients are displayed in Table 1 . Briefly, patients receiving platelets had a higher burden of comorbid disease, higher baseline SOFA scores, and more severe coagulation abnormalities. A total of 2115 patients (6.7%) received a qualifying RBC transfusion, including 1627 patients (5.3%) in the nonplatelet group and 488 (45.8%) in the platelettransfused group (P < .001). Results of univariate analyses in the nonmatched cohort are displayed in Supplemental Digital Content 2, Table 2 , http://links.lww.com/AA/ C203. Briefly, in unadjusted analyses, those receiving platelets were more likely to have an RBC transfusion, increased mortality, fewer ICU and hospital-free days, and smaller decreases in SOFA scores. The median RBC transfusion volume was 2 (1-2) units for both platelet-and nonplatelettransfused patients.
In total, 985 patients receiving prophylactic platelets were propensity-matched 1:1 with a patient not receiving platelets. Of note, 80 patients receiving a platelet component were removed from propensity-matched analyses due to the lack of a suitable nontransfused subject. Propensity matching largely removed between group differences resulting in similar covariate profiles (Table 1, Figure 2) . The results of propensity-matched analyses are displayed in Table 2 . Briefly, patients receiving platelets were more likely to receive an RBC transfusion (odds ratio 7.5; 95% confidence interval [CI], 5.9-9.5; P < .001), and experience fewer ICU-free days (mean [ Table 3 , http://links.lww. com/AA/C204, with platelet-transfused patients experiencing improvement only in the hematologic component with worsened respiratory, cardiovascular, and neurological component scores compared to nontransfused patients. There were no significant associations between platelet transfusion and mortality.
As a sensitivity analysis to the propensity score matching, a multivariable model was run in the full cohort adjusting for all variables used in the propensity score matching (Supplemental Digital Content 2, Table 2 , http://links. lww.com/AA/C203). The results were consistent with the primary analysis ( Table 2 ). Regarding those with marked thrombocytopenia, 1132 patients (3.6%) had a qualifying platelet count ≤50 × 10 9 /L, of which 478 (42%) received a platelet transfusion. There were 229 propensity matches where both the case and control had platelet counts ≤50 × 10 9 /L. When restricting analyses to these patients, platelet administration remained associated with increased RBC transfusion rates, but not with hospital or ICU-free days or SOFA scores (Table 3) . Similar results were seen at platelet counts ≤20 × 10 9 /L (Supplemental Digital Content 4, Table  4 , http://links.lww.com/AA/C205). The results of propensity-matched analyses restricted to medical or surgical ICU patients are displayed in Supplemental Digital Content 5, Table 5 , http://links.lww.com/AA/C206. Briefly, platelet administration was associated with higher odds for RBC transfusion in both environments, deterioration of 24-hour SOFA scores in the medical ICU, and decreased improvement in SOFA scores in surgical patients. When excluding patients who required surgery or invasive procedures, outcomes remained consistent with the primary analyses (Supplemental Digital Content 6, Table 6 , http://links.lww. com/AA/C207). As a post hoc analysis, we repeated the primary analysis adjusting for the effects of plasma transfusions administered in the 24 hours before or after platelet count measurement (nonplatelet-transfused group) or platelet transfusion (platelet-transfused group), and the results were similar with the exception of hospital mortality, which was now significantly higher in patients with prophylactic platelet transfusions (Supplemental Digital Content 7, Table  7 , http://links.lww.com/AA/C208).
Discussion
Thrombocytopenia is frequently encountered in the critically ill; however, the utility of platelet transfusions in the absence of bleeding remains unclear. In this investigation, prophylactic platelet transfusions were not associated with improved outcomes in a diverse cohort of critically ill patients. To the contrary, patients receiving platelets had higher rates of RBC transfusion in the subsequent 24 hours, fewer ICU and hospital-free days, and less improvement in SOFA scores. These relationships persisted in multiple Estimate and P value comes from negative binomial regression. A rate ratio <1 implies decreased mean for the outcome in those receiving platelet transfusions. Specifically, a rate ratio of 0.9 can be interpreted as a 10% decrease in the mean for those receiving platelet transfusions compared to those who did not.
predefined sensitivity analyses including limitation to medical or surgical ICU patients. In addition, similar results were seen with varying thresholds of thrombocytopenia. Platelets, as they exist innately in the human body, have increasingly been recognized for their beneficial effects on a variety of physiologic processes. Besides their impact on thrombosis and hemostasis, platelets also participate in inflammatory responses, enhance endothelial barrier function, and promote wound healing, tissue regeneration, and angiogenesis. 15, 16 It is therefore not surprising that thrombocytopenia has been identified as a poor prognostic marker for critically ill patients and has been utilized as a marker for organ impairment. 1, 4, 5, [16] [17] [18] [19] In the critically ill, the mechanisms driving thrombocytopenia are often multifactorial with platelet declines typically occurring as a consequence of underlying illness or in response to therapeutic interventions. Although platelet transfusions are frequently utilized for the quantitative restoration of platelet levels, the ability of platelet transfusions to restore normal platelet function and physiology remains unclear.
Bleeding is the most feared consequence of thrombocytopenia. While the thrombocytopenic patient with active bleeding is likely to benefit from platelet transfusion (though precise thresholds for transfusion remain poorly defined), there exists remarkable equipoise over the utility of platelet transfusions for nonbleeding patients with thrombocytopenia. From studies of patients with bone marrow hypoproliferation, spontaneous bleeding events are rare with platelet counts greater than 20 × 10 9 /L. 20 However, many patients receive prophylactic platelet transfusions at higher platelet counts. Indeed, clinically relevant platelet dysfunction may exist and potentially increase the risk of bleeding at higher platelet count levels in commonly encountered clinical scenarios (eg, trauma, septic shock, antiplatelet therapy). Conversely, severe thrombocytopenia is not always associated with increased rates of bleeding. Perhaps most notably, endothelial activation with associated release of von Willebrand Factor may compensate for low platelet numbers in those with severe liver disease. 21 It is therefore not particularly surprising that the thresholds utilized for platelet transfusion vary greatly among providers, with differing guidelines for platelet transfusion largely based on expert opinion. 6, 22, 23 In nonsurgical patients, the most widely identified platelet count threshold for transfusion is 10 × 10 9 /L; however, this is often increased to 20-30 × 10 9 /L for patients with additional risk factors for bleeding including severe hepatic or renal impairment or ongoing coagulopathy (ie, disseminated intravascular coagulation). 24, 25 In patients undergoing surgical or interventional procedures, even higher platelet counts are typically maintained (eg, 50-100 × 10 9 /L) in the immediate preoperative and postoperative periods despite the lack of compelling evidence to either support or refute this practice. 23, 26, 27 In the current investigation, which included a large and heterogeneous cohort of surgical and medical ICU patients, prophylactic platelet therapy was not associated with fewer bleeding complications in propensity-matched analyses. Conversely, patients who received prophylactic platelet therapy were more likely to receive an RBC transfusion in the ensuing 24 hours, with odds for this outcome 7 times greater than their nontransfused counterparts. This relationship remained after the exclusion of patients requiring surgical or interventional procedures in the ensuring 24 hours, and also after restricting the analyses to those patients with platelet counts ≤50 × 10 9 /L and 20 × 10 9 /L. While the driving factor behind the higher incidence of RBC transfusion seen in patients transfused with platelets remains unclear, there are several possible explanations. The first relates to provider-specific transfusion practices, such that providers with greater tendency to administer platelets prophylactically were also perhaps more inclined to transfuse erythrocytes. While plausible, this relationship remains conjectural. It may also be that patients receiving platelet transfusion were more critically ill than their nontransfused counterparts, despite successful propensity matching including near identical pretransfusion SOFA scores, comorbidity profiles, and laboratory characteristics including hemoglobin concentrations. As an alternative explanation, it is possible that platelet transfusion contributed to hemodilution, which in some patients may have dropped hemoglobin values below thresholds for RBC transfusion; however, it must also be recognized Estimate and P value comes from negative binomial regression. A rate ratio <1 implies decreased mean for the outcome in those receiving platelet transfusions. Specifically, a rate ratio of 0.9 can be interpreted as a 10% decrease in the mean for those receiving platelet transfusions compared to those who did not. www.anesthesia-analgesia.org
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Prophylactic Platelets in the Critically Ill that platelet components are not a particularly high-volume transfusion product. In addition to increased RBC transfusion rates, platelettransfused patients had fewer ICU and hospital-free days and less improvement in their SOFA scores in the ensuing 24 hours, suggesting that platelet transfusion did not result in improved clinical outcomes. This was seen in both medical and surgical ICU populations. Interestingly, platelettransfused patients had inferior SOFA component scores after transfusion in every organ system except for the renal system, with equivalent scores between groups, and the hematologic system, in which platelet-transfused patients experienced improved scores directly attributed to higher platelet counts after transfusion.
There are several notable limitations of this investigation. The first relates to the retrospective design which does not allow for the precise determination of the indications for transfusion therapies. As such, some platelet transfusions may have been given in response to active hemorrhage rather than for the prevention of future bleeding complications. In an attempt to limit this possibility, we excluded any patient who received RBC transfusion in the 24-hour period preceding platelet count measurement or platelet transfusion, assuming that most patients with active bleeding secondary to thrombocytopenia would receive RBCs in addition to platelets. Of note, this may have also inadvertently excluded some nonbleeding patients from further analyses. Additionally, the primary outcome measure of RBC transfusion was utilized as a surrogate for bleeding, but patients may have been transfused for other reasons (eg, anemia of chronic disease, dilutional anemia). However, given that both groups had similar baseline hemoglobin values and comorbidity profiles in matched analyses, differences in RBC transfusion rates are unlikely to be explained entirely by the heterogeneity of providerresponses to stable, nonbleeding anemia. Other surrogates for bleeding complications such as hemoglobin and hematocrit levels were not utilized given concerns for variation based on the presence of other common clinical factors (eg, crystalloid and nonblood colloid administration, phlebotomy, diuresis). Documented bleeding episodes (eg, gastrointestinal hemorrhage) were not included given lack of standardization for reporting in our electronic health record environment, resulting in an inability to objectively identify events. Another limitation related to the retrospective nature of this study is the potential for residual confounding. Despite careful propensity matching on observed variables, the possibility for residual confounding persists such that the platelet-transfused group could have been representative of a sicker patient population. Additionally, international normalized ratio and aPTT values were missing for 20% and 35% of patients, respectively, and these missing variables were imputed. Significant differences were noted when patients with any missing were compared to nonmissing, including prophylactic platelet transfusion, aspirin use, warfarin use, and gender. The data were assumed to be missing at random, but this assumption could not be tested, and may have biased our results. Moreover, due to the paucity of patients with platelet counts <10 × 10 9 /L who did not receive prophylactic platelets (n = 2), we could not assess the utility of platelet transfusion at such severe levels of thrombocytopenia. Hence, we were only able to assess the impact of prophylactic platelet transfusions utilizing a minimum platelet count threshold of 20 × 10 9 /L, and are unable to comment on the utility of platelet transfusion for platelet counts below 10 × 10 9 /L. Other limitations include some of the sensitivity analyses being underpowered, and the power of the propensity score matched samples being somewhat limited. The observed odds ratios of 1.2 for allcause 30-day mortality and 1.1 for ICU mortality may be clinically important, but the study was not powered to detect differences that small. Notably, the same estimates were significant when analyzing the full cohort in multivariable models that adjusted for variables. Finally, it must be acknowledged that while clinical trajectories did not improve for the cohort as a whole after platelet transfusion, it is possible that certain subpopulations may indeed benefit from the intervention, though these subgroups have yet to be identified.
Conclusions
Prophylactic platelet transfusion in a large cohort of medical and surgical ICU patients was not associated with fewer bleeding complications or improved clinical outcomes. Conversely, patients receiving platelet therapy were more likely to receive RBCs in the subsequent 24 hours, experience less improvement in organ function, and spend more time in the ICU and hospital. In light of these findings, more conservative management of thrombocytopenia may be warranted in nonbleeding critically ill patients. Clinical trials specifically addressing this important knowledge gap are critically needed. E
